LEADER 03413nam  2200601Ia 450 
001 9910779233003321
005 20230721020721.0
010   $a0-19-176873-1
010   $a1-283-57977-4
010   $a9786613892225
010   $a0-19-157532-1
035   $a(CKB)2550000000105396
035   $a(EBL)975667
035   $a(OCoLC)801363491
035   $a(SSID)ssj0000692058
035   $a(PQKBManifestationID)11363258
035   $a(PQKBTitleCode)TC0000692058
035   $a(PQKBWorkID)10634917
035   $a(PQKB)11649804
035   $a(StDuBDS)EDZ0000128746
035   $a(MiAaPQ)EBC975667
035   $a(Au-PeEL)EBL975667
035   $a(CaPaEBR)ebr10581387
035   $a(CaONFJC)MIL389222
035   $a(EXLCZ)992550000000105396
100   $a20081106d2009      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aOpioids in cancer pain$b[electronic resource] /$fedited by Mellar Davis ... [et al
205   $a2nd ed.
210   $aOxford ;$aNew York $cOxford University Press$d2009
215   $a1 online resource (500 p.)
300   $aDescription based upon print version of record.
311   $a0-19-923664-X 
320   $aIncludes bibliographical references and index.
327   $aContributors; List of abbreviations; 1 Opioid receptors and opioid pharmacodynamics; 2 Opioid pharmacokinetics; 3 Liver disease and exogenous opioid pharmacokinetics; 4 Opioids in renal failure; 5 Codeine; 6 Hydrocodone; 7 Tramadol; 8 Dextropropoxyphene; 9 Morphine; 10 Oxycodone; 11 The lipophilic opioids: fentanyl, alfentanil, sufentanil, and remifentanil; 12 Buprenorphine; 13 Methadone; 14 Hydromorphone; 15 Levorphanol; 16 Diamorphine; 17 Oxymorphone; 18 Choice of opioids and the WHO ladder; 19 Pharmacogenetics and opioids; 20 Opioid rotation; 21 Equi-analgesia. 22 Dosing strategies for acute pain23 Opioid dosing strategies for chronic pain and the management of opioid side effects; 24 Patient-controlled analgesia; 25 Spinal opioids in cancer pain; 26 Opioid poorly responsive pain, physical dependence, tolerance, and opioid-induced hyperalgesia; 27 Opioids in special populations: developing countries; 28 Opioids in special populations: paediatric population; 29 Opioids in the terminal phase; 30 Cancer pain and substance abuse; Index; A; B; C; D; E; F; G; H; I; K; L; M; N; O; P; Q; R; S; T; U; V; W; X.
330   $aOpioids have become invaluable in modern medicine but it is essential that they are prescribed with an understanding of the complex pharmacology behind their effectiveness; without this, they will frequently fail to achieve their enormous potential of pain relief, minimal side effects, and improved function. In addition, opioids come with problems, including side effects such as constipation, respiratory depression, and sedation, as well as the potential for substance abuse.Clinicians handling the complex pain problems of cancer patients must incorporate the insight of basic scientists and pha
606   $aCancer pain$xTreatment
606   $aOpioids
615  0$aCancer pain$xTreatment.
615  0$aOpioids.
676   $a616.994061
701   $aDavis$b Mellar P$01462010
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910779233003321
996   $aOpioids in cancer pain$93670859
997   $aUNINA